Navigation Links
Cell Signaling Technology Releases Four Monoclonal Antibodies for Immunometabolism and Tumor Immunology Research

Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, released four new monoclonal antibodies relevant to the rapidly growing fields of immunometabolism and tumor immunology.

CST has released Arginase-1 (D4E3M™ XP® #93668, LAG3 (D2G4O™) #15372, ICOS (D1K2T™) (IHC Specific) #89601, and PD-L1 (D5V3B) (Mouse Specific; IHC Specific) #64988 rabbit monoclonal antibodies (mAbs). These rabbit mAbs complement CST’s expanding portfolio of products that support tumor immunology research, including antibodies detecting the PD-1/PD-L1 family of immune checkpoint proteins, as well as metabolic targets, such as IDO, that have been proposed to promote immune suppression within the tumor microenvironment. Introduction of ICOS rabbit mAb also highlights the growing list of antibodies that detect co-stimulatory molecules, such as CD40L, OX40, and OX40L that research studies have demonstrated to have a role in augmenting anti-tumor immune responses.

All four newly released antibodies are recommended for immunohistochemistry (IHC), an application that helps visualize protein expression in the context of preserved tissue architecture, which is key to the translational research community interested in the study of tumor immunology.

Notably, the newly released Arginase-1 rabbit mAb exhibits mouse as well as human reactivity, while the new rabbit mAb targeting PD-L1 demonstrates exclusive specificity to mouse tissue, a critical feature to enable pre-clinical studies, typically carried out in murine models of disease.

CST’s recent announcement introducing the company’s capabilities to produce stringently characterized GMP-grade recombinant rabbit monoclonal antibodies further reinforces the impact that Arginase-1, LAG3, ICOS, PD-L1, and other related antibodies from CST could have on fostering the transition from basic to translational research.

“With the release of these antibodies, we are continuing to build on a rich repertoire of products that are highly enabling to the research community interested in tumor immunology. Our goal is to help scientists understand how tumors interact with the cells of the immune system and how ancillary immunosuppressive factors promote tumor growth. We hope that this understanding may help inform better treatment strategies for many cancers,” said Michael J. Comb, CEO of CST.

About CST
Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan.

D4E3M™ D2G4O™ D1K2T, XP®, Cell Signaling Technology®, and CST™ are trademarks of Cell Signaling Technology, Inc.

Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related biology technology :

1. Review of a New SkinCare Gel that uses Redox Signaling Technology
2. CEDs Mid-Year Update to its Innovators Report Shows NC Startups Attracting Investment From Across the Globe with Several High-Profile Investment Deals, IPOs and Acquisitions Signaling Strength of Entrepreneurial Sector
3. Study Reports Significant Reduction in Stress via Electrical Neurosignaling
4. Publication in Nature Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway in Neuronal Biology
5. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
6. Verdad Media’s Unique MANIS Technology Means Better Reputation Management Results for Clients
7. Greenphires ClinCard Technology Platform selected by Bavarian Nordic for Major Vaccine Trial
8. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
9. Annual Conference about Technology Solutions for People with Disabilities Announces Program
10. Washington State University to Present on Tin Nanoneedles: A Technology for Lithium-ion Batteries, at Knowledge Foundation’s Next Generation Batteries 2013 Conference
11. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
Post Your Comments:
(Date:8/14/2019)... ... August 13, 2019 , ... INDIGO Biosciences, Inc. ... solutions, announced the appointment of Mark McLoughlin to the Company’s Board of Directors. ... McLoughlin will lend his healthcare expertise and extensive background in laboratory and scientific ...
(Date:8/7/2019)... ... ... Locus Agricultural Solutions (Locus AG) reports record levels of carbon sequestered in ... ® , which is pulling up to 121% more carbon into the soil than ... from the treatment of almonds, cherries, turf/sod, grapes and citrus across the U.S., as ...
(Date:8/6/2019)... ... August 05, 2019 , ... Advanced Clinical, a ... a distinguished leader by PharmaVOICE magazine, earning him a prestigious spot on the ... July/August special issue. , As the executive vice president of business development and ...
(Date:7/30/2019)... ... July 30, 2019 , ... The summer ... cooking events company. Not only has the company already hosted many of its ... Cooking Parties to its guests. , With Lajollacooks4u’s Private Cooking Parties, guests prepare ...
Breaking Biology Technology:
(Date:8/15/2019)... ... , ... Deep Science Ventures (DSV), a new paradigm for applied ... dedicated to building 100 companies over the next 10 years to address the urgent ... Deep Science Ventures was founded to create a better method for launching science companies; ...
(Date:8/14/2019)... ... ... Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research in ... learn about two common imaging methods in NAFLD/NASH to aid with early disease diagnosis, ... disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided into simple ...
(Date:8/9/2019)... ... August 09, 2019 , ... With a demand in ... and more patients will visit urgent care centers (UCC) in the coming years, according ... report, The Market for Urgent Care Centers , is a detailed look at ...
Breaking Biology News(10 mins):